Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Rating) was the target of a large decrease in short interest during the month of February. As of February 15th, there was short interest totalling 24,400 shares, a decrease of 62.6% from the January 31st total of 65,200 shares. Approximately 0.3% of the company’s stock are short sold. Based on an average daily trading volume, of 52,000 shares, the days-to-cover ratio is presently 0.5 days.

Institutional Trading of Xilio Therapeutics

Large investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its position in shares of Xilio Therapeutics by 47.7% during the 1st quarter. Bank of New York Mellon Corp now owns 21,029 shares of the company’s stock valued at $149,000 after acquiring an additional 6,791 shares during the last quarter. Morgan Stanley raised its holdings in shares of Xilio Therapeutics by 274.4% during the 4th quarter. Morgan Stanley now owns 25,611 shares of the company’s stock valued at $69,000 after buying an additional 18,771 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Xilio Therapeutics by 30.2% during the 4th quarter. Renaissance Technologies LLC now owns 37,100 shares of the company’s stock valued at $100,000 after buying an additional 8,600 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Xilio Therapeutics during the 2nd quarter valued at about $146,000. Finally, State Street Corp raised its holdings in shares of Xilio Therapeutics by 58.5% during the 1st quarter. State Street Corp now owns 93,861 shares of the company’s stock valued at $664,000 after buying an additional 34,651 shares in the last quarter. Institutional investors own 60.46% of the company’s stock.

Xilio Therapeutics Stock Down 2.4 %

Shares of NASDAQ XLO opened at $3.61 on Wednesday. Xilio Therapeutics has a 52 week low of $1.95 and a 52 week high of $12.29. The business has a 50-day simple moving average of $3.09 and a two-hundred day simple moving average of $2.69. The company has a quick ratio of 8.45, a current ratio of 8.45 and a debt-to-equity ratio of 0.04. The company has a market cap of $99.17 million, a P/E ratio of -1.07 and a beta of 0.32.

Wall Street Analyst Weigh In

XLO has been the subject of a number of analyst reports. Guggenheim lowered their price target on Xilio Therapeutics to $15.00 in a research report on Tuesday, November 15th. Chardan Capital began coverage on Xilio Therapeutics in a research report on Wednesday, December 21st. They set a “buy” rating and a $7.00 target price for the company. Raymond James decreased their target price on Xilio Therapeutics from $31.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, November 10th. Finally, Morgan Stanley decreased their target price on Xilio Therapeutics from $20.00 to $10.00 and set an “overweight” rating for the company in a research report on Friday, January 27th.

Xilio Therapeutics Company Profile

(Get Rating)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.